|
Gene: LDHB |
Gene summary for LDHB |
Gene summary. |
Gene information | Species | Human | Gene symbol | LDHB | Gene ID | 3945 |
Gene name | lactate dehydrogenase B | |
Gene Alias | HEL-S-281 | |
Cytomap | 12p12.1 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | P07195 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3945 | LDHB | GSM4909282 | Human | Breast | IDC | 8.86e-05 | 2.64e-01 | -0.0288 |
3945 | LDHB | GSM4909285 | Human | Breast | IDC | 1.22e-11 | 4.03e-01 | 0.21 |
3945 | LDHB | GSM4909287 | Human | Breast | IDC | 1.92e-08 | 2.31e-01 | 0.2057 |
3945 | LDHB | GSM4909288 | Human | Breast | IDC | 2.12e-04 | -4.08e-02 | 0.0988 |
3945 | LDHB | GSM4909291 | Human | Breast | IDC | 3.69e-30 | -8.53e-01 | 0.1753 |
3945 | LDHB | GSM4909292 | Human | Breast | IDC | 3.05e-04 | -7.98e-01 | 0.1236 |
3945 | LDHB | GSM4909294 | Human | Breast | IDC | 5.73e-26 | -6.25e-01 | 0.2022 |
3945 | LDHB | GSM4909296 | Human | Breast | IDC | 5.55e-43 | -8.36e-01 | 0.1524 |
3945 | LDHB | GSM4909297 | Human | Breast | IDC | 2.07e-29 | -3.46e-01 | 0.1517 |
3945 | LDHB | GSM4909298 | Human | Breast | IDC | 1.54e-17 | -5.92e-01 | 0.1551 |
3945 | LDHB | GSM4909301 | Human | Breast | IDC | 6.68e-35 | -7.83e-01 | 0.1577 |
3945 | LDHB | GSM4909302 | Human | Breast | IDC | 3.87e-36 | -7.79e-01 | 0.1545 |
3945 | LDHB | GSM4909304 | Human | Breast | IDC | 5.59e-34 | -7.40e-01 | 0.1636 |
3945 | LDHB | GSM4909306 | Human | Breast | IDC | 3.71e-12 | -5.16e-01 | 0.1564 |
3945 | LDHB | GSM4909307 | Human | Breast | IDC | 1.20e-20 | -6.22e-01 | 0.1569 |
3945 | LDHB | GSM4909308 | Human | Breast | IDC | 5.47e-25 | -7.31e-01 | 0.158 |
3945 | LDHB | GSM4909309 | Human | Breast | IDC | 2.54e-03 | -3.56e-01 | 0.0483 |
3945 | LDHB | GSM4909311 | Human | Breast | IDC | 3.41e-51 | -8.37e-01 | 0.1534 |
3945 | LDHB | GSM4909312 | Human | Breast | IDC | 2.28e-44 | -8.19e-01 | 0.1552 |
3945 | LDHB | GSM4909313 | Human | Breast | IDC | 5.11e-11 | -5.56e-01 | 0.0391 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa006209 | Oral cavity | OSCC | Pyruvate metabolism | 31/3704 | 47/8465 | 1.74e-03 | 4.73e-03 | 2.41e-03 | 31 |
hsa0001014 | Oral cavity | OSCC | Glycolysis / Gluconeogenesis | 40/3704 | 67/8465 | 6.08e-03 | 1.44e-02 | 7.31e-03 | 40 |
hsa0523017 | Oral cavity | OSCC | Central carbon metabolism in cancer | 49/3704 | 70/8465 | 7.57e-06 | 3.59e-05 | 1.83e-05 | 49 |
hsa04066112 | Oral cavity | OSCC | HIF-1 signaling pathway | 68/3704 | 109/8465 | 6.30e-05 | 2.48e-04 | 1.26e-04 | 68 |
hsa0062012 | Oral cavity | OSCC | Pyruvate metabolism | 31/3704 | 47/8465 | 1.74e-03 | 4.73e-03 | 2.41e-03 | 31 |
hsa0001015 | Oral cavity | OSCC | Glycolysis / Gluconeogenesis | 40/3704 | 67/8465 | 6.08e-03 | 1.44e-02 | 7.31e-03 | 40 |
hsa0523023 | Oral cavity | LP | Central carbon metabolism in cancer | 31/2418 | 70/8465 | 3.50e-03 | 1.46e-02 | 9.40e-03 | 31 |
hsa0062022 | Oral cavity | LP | Pyruvate metabolism | 22/2418 | 47/8465 | 5.88e-03 | 2.31e-02 | 1.49e-02 | 22 |
hsa0001023 | Oral cavity | LP | Glycolysis / Gluconeogenesis | 28/2418 | 67/8465 | 1.36e-02 | 4.44e-02 | 2.86e-02 | 28 |
hsa0406628 | Oral cavity | LP | HIF-1 signaling pathway | 42/2418 | 109/8465 | 1.52e-02 | 4.75e-02 | 3.06e-02 | 42 |
hsa0523033 | Oral cavity | LP | Central carbon metabolism in cancer | 31/2418 | 70/8465 | 3.50e-03 | 1.46e-02 | 9.40e-03 | 31 |
hsa0062032 | Oral cavity | LP | Pyruvate metabolism | 22/2418 | 47/8465 | 5.88e-03 | 2.31e-02 | 1.49e-02 | 22 |
hsa0001033 | Oral cavity | LP | Glycolysis / Gluconeogenesis | 28/2418 | 67/8465 | 1.36e-02 | 4.44e-02 | 2.86e-02 | 28 |
hsa0406636 | Oral cavity | LP | HIF-1 signaling pathway | 42/2418 | 109/8465 | 1.52e-02 | 4.75e-02 | 3.06e-02 | 42 |
hsa0406661 | Oral cavity | NEOLP | HIF-1 signaling pathway | 27/1112 | 109/8465 | 6.86e-04 | 3.58e-03 | 2.25e-03 | 27 |
hsa0406671 | Oral cavity | NEOLP | HIF-1 signaling pathway | 27/1112 | 109/8465 | 6.86e-04 | 3.58e-03 | 2.25e-03 | 27 |
hsa0406625 | Prostate | BPH | HIF-1 signaling pathway | 40/1718 | 109/8465 | 4.97e-05 | 3.35e-04 | 2.07e-04 | 40 |
hsa0523014 | Prostate | BPH | Central carbon metabolism in cancer | 23/1718 | 70/8465 | 9.13e-03 | 2.84e-02 | 1.76e-02 | 23 |
hsa0492212 | Prostate | BPH | Glucagon signaling pathway | 32/1718 | 107/8465 | 1.13e-02 | 3.43e-02 | 2.12e-02 | 32 |
hsa04066111 | Prostate | BPH | HIF-1 signaling pathway | 40/1718 | 109/8465 | 4.97e-05 | 3.35e-04 | 2.07e-04 | 40 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LDHB | SNV | Missense_Mutation | novel | c.750N>A | p.Asn250Lys | p.N250K | P07195 | protein_coding | deleterious(0.04) | probably_damaging(0.955) | TCGA-OL-A66P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
LDHB | SNV | Missense_Mutation | c.425N>G | p.Asp142Gly | p.D142G | P07195 | protein_coding | deleterious(0.04) | probably_damaging(0.995) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
LDHB | SNV | Missense_Mutation | novel | c.182N>A | p.Gly61Glu | p.G61E | P07195 | protein_coding | deleterious(0.01) | probably_damaging(0.969) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LDHB | SNV | Missense_Mutation | novel | c.610N>T | p.Gly204Cys | p.G204C | P07195 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LDHB | SNV | Missense_Mutation | rs200163319 | c.473G>A | p.Arg158His | p.R158H | P07195 | protein_coding | tolerated(0.12) | benign(0.318) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LDHB | SNV | Missense_Mutation | novel | c.503N>A | p.Ser168Tyr | p.S168Y | P07195 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
LDHB | SNV | Missense_Mutation | c.832G>T | p.Val278Leu | p.V278L | P07195 | protein_coding | tolerated(0.08) | benign(0.175) | TCGA-G5-6233-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
LDHB | insertion | Frame_Shift_Ins | novel | c.833dupT | p.Met281AspfsTer5 | p.M281Dfs*5 | P07195 | protein_coding | TCGA-G5-6233-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PD | ||
LDHB | SNV | Missense_Mutation | c.104N>T | p.Ala35Val | p.A35V | P07195 | protein_coding | deleterious(0.04) | possibly_damaging(0.461) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
LDHB | SNV | Missense_Mutation | rs532712842 | c.472C>T | p.Arg158Cys | p.R158C | P07195 | protein_coding | tolerated(0.08) | possibly_damaging(0.51) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |